FDA and FTC warned Kratom Exchange that it sells kratom as unapproved new drugs for opioid addiction and other conditions.
What happened
FDA reviewed the company’s website in May 2022 and FTC reviewed it in June 2022; FDA also reviewed the company’s Twitter account. The letter says the website took orders for kratom powders and made claims that they treat opioid addiction and withdrawal, depression, high blood pressure, and other conditions. FDA says there are no FDA-approved applications for any of the kratom products.
What FDA found
The kratom products are drugs because the company intended them to cure, mitigate, treat, or prevent disease or affect body structure or function.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The kratom products are unapproved new drugs sold without FDA approval.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d); section 201(p), 21 U.S.C. 321(p)The website and Twitter claims say kratom treats opioid addiction and withdrawal, depression, high blood pressure, and other conditions.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)FTC says the addiction-treatment claims lack competent and reliable scientific evidence, including well-controlled human clinical studies.
FTC Act, 15 U.S.C. §§ 41–57FTC says deceptive claims about treating substance use disorder can lead to civil penalties.
Opioid Addiction Recovery Fraud Prevention Act of 2018, 15 U.S.C. § 45d
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence. FTC asks for notice within 15 working days of actions taken and says to immediately stop all such claims.
Who should pay attention
- kratom retailers and online marketers
- brands making addiction or withdrawal claims for botanicals
- companies selling supplements with disease-treatment claims
This is a summary. Read the original letter on fda.gov.